MedTrace Logo

Chart Review Study to Describe the Clinical Profile of Idiopathic Pulmonary Fibrosis (IPF) Patients Treated With Nintedanib (OFEV®) in Real-world Practice in Spain

NCT03281200 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 172

Last updated 2019-08-01

Study results available
· View outcomes & findings →

Summary

The present study has been designed to characterize IPF patients treated with nintedanib (OFEV®), at time of treatment initiation, with respect to their clinical profile based on real-world data from January 2016 in Spanish Pulmonology Services.

Conditions

Interventions

DRUG

L - Antineoplastic and immunomodulating agents

L - Antineoplastic and immunomodulating agents

DRUG

L01 - Antineoplastic agents

L01 - Antineoplastic agents

DRUG

L01X - Other antineoplastic agents

L01X - Other antineoplastic agents

DRUG

L01XE - Protein kinase inhibitors

L01XE - Protein kinase inhibitors

DRUG

L01XE31 - Nintedanib

L01XE31 - Nintedanib

Sponsors & Collaborators

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-24
Primary Completion
2018-06-07
Completion
2018-06-07
FDA Drug
Yes

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03281200 on ClinicalTrials.gov